New study aims to uncover hidden liver risks of immunotherapy

NCT ID NCT04476563

Recruiting now Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 160 cancer patients to understand why some develop liver injury from checkpoint inhibitor drugs. Researchers will track blood markers and genetic factors to identify who is at risk. No new treatment is tested; the goal is to improve diagnosis and monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHECKPOINT INHIBITOR-INDUCED LIVER INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis drug-induced liver injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE-MEDIATED HEPATITIS

Contacts and locations

Locations

University of Nottingham
RECRUITING

Nottingham, NG72RD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.